• Vaxart won a new European patent covering key technology behind its oral recombinant norovirus vaccine candidate.
• The European Patent Office published the grant of European Patent No. 3791859 effective today.
• Protection runs through at least 2036 across 13 European jurisdictions, including Germany, France, Italy, Spain, the UK.
• The patent covers aspects of Vaxart’s room-temperature stable, needle-free pill platform for norovirus.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxart Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608261607PRIMZONEFULLFEED9816732) on August 26, 2026, and is solely responsible for the information contained therein.